Takeda and Denali Partnering on Development of Three Alzheimer’s Therapies

Takeda and Denali Partnering on Development of Three Alzheimer’s Therapies
Takeda Pharmaceutical Company and Denali Therapeutics are teaming up to develop three treatments for Alzheimer’s disease and other neurodegenerative diseases. They will use Denali’s Antibody Transport Vehicle technology to get the therapies past the blood-brain barrier so they are able to work where they are needed — in the brain. The barrier is a membrane that separates blood from the brain and central nervous system fluids. It prevents bacteria and other invaders from reaching the brain. But it allows beneficial substances such as water, certain gases and molecules to reach the brain, along with glucose and amino ac
Subscribe or to access all post and page content.

One comment

  1. Joanne Silver says:

    My husband is in late stage Alzheimer’s, is mostly nonverbal, has lost the ability to stand and walk, etc. He still recognizes people that he sees frequently, responds with his dominant hand. Could he be included in any trials? Is there any hope for him?

Leave a Comment

Your email address will not be published. Required fields are marked *